Until now, it was unclear to what extent Natural killer cells contribute to the development of severe COVID-19 infection. Scientists of the University of Bonn and the German Center for Neurodegenerative Diseases (DZNE), together with an international team, have now been able to investigate in detail the role of NK cells in the course of COVID-19 in a multicenter study.
Persistent dysfunction in severe COVID-19 courses
"Already in the very early stage of severe disease, NK cells display a specific molecular fingerprint that is attributable to the so-called type I interferons. This is accompanied by a significant dysfunction that persists for several weeks," says Prof. Dr. Jacob Nattermann, study leader and Deputy Director of the Department of Internal Medicine I of the University Hospital Bonn.
The researchers examined blood samples from 205 subjects between the 1st and 6th week after symptom onset. This allowed them to classify the molecular properties and functions of the cells over time.
"NK cells from COVID-19 patients with moderate symptoms also showed an impaired function at the beginning of the disease, but this normalized after a short time," reports Prof. Dr. Joachim Schultze, co-leader of the study and Director of Systems Medicine at the DZNE.
NK cells lose antifibrotic activity
Since severe COVID-19 infection is usually accompanied by tissue remodeling in the lung (pulmonary fibrosis) and NK cells are known for their antifibrotic properties, this aspect was also investigated. "Three weeks after infection, molecular patterns resembling those observed in other immune cells in the context of fibrosis formation were evident in NK cells in severe courses. In line with these observations, these NK cells have significantly lost their antifibrotic capacity, which may have an impact in fibrotic remodeling of the lung," added Dr. Anna Aschenbrenner, also co-leader of the study and working at the Life & Medical Sciences (LIMES) Institute of the University of Bonn and at DZNE.
"In summary, our data provide a detailed insight into the role of NK cells in the immunopathogenesis of COVID-19. Future study will have to show whether this may aid the development of novel therapeutic approaches," said Dr. Benjamin Krämer, one of the first authors from the Department of Internal Medicine I of the University Hospital Bonn.
National and international cooperation
"The COVID-19 emergency taught us that collaborating with some of the best groups in Germany and around the world allows us to achieve clinically important results at an unprecedented pace. We will continue to work in this way on NK cells, but also on other cell types,” comment co-first authors Rainer Knoll and Dr. Lorenzo Bonaguro, both from DZNE. "This will hopefully also allow us to understand how these different cells interact in severe COVID-19 and allow us to fully understand this complicated disease," further remark co-first authors Michael ToVinh and Jan Raabe, both PhD students at the Department of Internal Medicine I of the University Hospital Bonn.
Participating institutions and funding
In addition other national and international groups from the following centers participated: Bonn University Hospital (PD Dr. Beate Kümmerer, Dr. Florian Schmidt, Prof. Dr. Eicke Latz), Charité Berlin (Prof. Dr. Leif Erik Sander, Prof. Dr. Birgit Sawitzki), Kiel University Hospital (Prof. Dr. Philipp Rosenstiel), Düsseldorf University Hospital (Prof. Dr. Verena Keitel), Newcastle University (Prof. Dr. Muzlifah Haniffa), and the University of Washington (Prof. Dr. James R. Heath). The study was funded by the German Research Foundation (DFG), the German Federal Ministry of Education and Research (BMBF), the German Center for Infection Research (DZIF) and the DZNE.
Publication: “Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19”, Immunity, DOI: 10.1016/j.immuni.2021.09.002, Link zur Studie:
https://www.sciencedirect.com/science/article/pii/S1074761321003654?via%3Dihub
Contact:
Prof. Dr. Jacob Nattermann
Hepatogastroenterologie
Medizinische Klinik und Poliklinik I
Uniklinikum Bonn
Tel.: +49 (0)228 287 -12230
E-Mail: jacob.nattermann@ukbonn.de
Prof. Dr. Joachim Schultze
Direktor Systemmedizin
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)
Tel.: +49 (0) 228 43302-410
E-Mail: joachim.schultze@dzne.de
